Seletracetam – Kodiac biolabs

Plain-language summaryIntrigue 36 / 100

Seletracetam is a difluorovinyl racetam developed by UCB as a higher-potency successor to levetiracetam. It binds SV2A with greater affinity. Development was halted in favor of brivaracetam. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

31/100

A discontinued SV2A also-ran with narrow probe value and no active development path

Look, seletracetam is basically a pharmaceutical footnote. UCB developed it in parallel with brivaracetam, both targeting the same SV2A binding site that levetiracetam had already validated. The difluorovinyl substituent at the pyrrolidinone 4-position is genuinely clever chemistry, delivering roughly 10-fold higher SV2A affinity than levetiracetam in binding assays. But here’s the thing: that advantage didn’t translate into a clinical win. Phase 2 data in partial-onset seizures showed efficacy that was essentially comparable to brivaracetam, with a slightly less favorable safety read. UCB made the call in 2007 to advance brivaracetam, which is now an approved antiseizure agent with a real regulatory package behind it. Seletracetam went on the shelf.

The SV2A story itself has become mature. When levetiracetam launched in 1999 the mechanism was genuinely mysterious, which is part of what made the class interesting. By the time brivaracetam hit Phase 3 the mechanism was well-characterized: modulation of synaptic vesicle protein 2A, reduction in neurotransmitter exocytosis at high firing frequencies. That’s solid biology, but it’s no longer frontier biology. Seletracetam doesnt add a new dimension to the mechanism, it just sits at a different point on the affinity curve.

The differentiation problem is the real killer here. The compound’s most direct comparator, brivaracetam, is FDA-approved, commercially available in clinical quantities, and has a mountain of safety and PK data. For any lab doing SV2A pharmacology work, brivaracetam is the obvious tool. Seletracetam could be interesting for structure-activity relationship studies specifically around the difluorovinyl scaffold, or as a comparator in displacement assays, and we think that narrow use case is real. But its bench value tops out there.

What we don’t like: the evidence base is frozen at Phase 2. No multi-lab replication of human data, no Phase 3 package, and nothing published in the last decade that moves the needle. The preclinical literature is thin outside of UCB’s own publications. The program closure was commercial, not mechanistic, so we’re not penalizing seletracetam for a disproven mechanism. SV2A agonism clearly works. The problem is brivaracetam already demonstrates that, better and with more data behind it.

Honestly, if you’re studying SV2A pharmacology, seletracetam is a reasonable secondary probe to keep in the toolkit. The affinity advantage matters in some displacement paradigms, and the structural comparison with brivaracetam is instructive for SAR work. But it’s not a compound that drives a research program. It’s a supporting actor in someone else’s story, and that story ended with brivaracetam’s NDA approval in 2016.

Novelty: 25
Mechanism promise: 30
In-category differentiation: 20
Evidence quality: 40
Translational signal: 45
Research bench value: 35

Rationale Seletracetam scores low primarily on novelty and differentiation: it lost an internal head-to-head against brivaracetam in 2007 and the program has been frozen ever since, leaving it as a structural curiosity in a now-mature receptor class. Its Phase 2 clinical data and 10x SV2A affinity advantage over levetiracetam rescue it from the bottom, but barely.

Difluorovinyl pyrrolidinone (high-affinity SV2A ligand)

A second-generation UCB SV2A ligand discontinued after Phase 2 due to commercial considerations despite favorable efficacy.

Abstract

Seletracetam (UCB 44212; (2S)-2-[(4R)-4-(2,2-difluorovinyl)-2-oxopyrrolidin-1-yl]butanamide; CAS 357336-74-4; molecular formula C10H14F2N2O2; molecular weight 232.23) is a second-generation SV2A ligand developed at UCB Pharma in parallel with brivaracetam. The compound features a difluorovinyl substituent at the pyrrolidinone 4-position, producing approximately 10-fold higher SV2A affinity than levetiracetam. Phase 2 trials in partial-onset seizures showed efficacy comparable to brivaracetam, but UCB discontinued the program in 2007 in favor of brivaracetam, which had a slightly more favorable safety profile in the development program. The compound is not approved by any regulatory authority and has no continuing clinical development. It is sold as a research chemical for investigational use. Pharmacokinetics in Phase 2 showed plasma half-life of approximately 8 hours and oral bioavailability above 80 percent. The compound provides an interesting case study in pharmaceutical decision-making where two structurally similar compounds with similar efficacy profiles led to selection of one for marketing.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-036Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.